Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore G Karrison

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2013
Estimation of progression-free survival in the randomized discontinuation trial designTheodore G Karrison
Lifetime Data Analysis|January 12, 2022
Nonparametric inference in the accelerated failure time model using restricted meansMihai C Giurcanu, Theodore G Karrison
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Testing the wrong hypothesis in phase II oncology trials: there is a better alternativeMark J Ratain, Theodore G Karrison
Journal of the National Cancer Institute|February 25, 2015
Building firm foundations for therapy developmentJames J Dignam, Theodore G Karrison
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
There Is More to Length of Survival Than Survival: Endpoints in Oncology TrialsWalter M Stadler, Theodore G Karrison
Controlled Clinical Trials|September 23, 2003
A group sequential, response-adaptive design for randomized clinical trialsTheodore G Karrison, Dezheng Huo, Rick Chappell
Blood Advances|June 21, 2022
D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemiaDaniela R Anderson, Wendy Stock, Theodore G Karrison, et al.
Journal of the National Cancer Institute|September 27, 2007
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancerTheodore G Karrison, Michael L Maitland, Walter M Stadler, et al.
Genetic Epidemiology|November 5, 2013
Quantitative allelic test--a fast test for very large association studiesSang Mee Lee, Theodore G Karrison, Nancy J Cox, et al.
The American Statistician|September 17, 2013
Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial DesignTheodore G Karrison, Mark J Ratain, Walter M Stadler, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 16, 2013
Estimation of progression-free survival in the randomized discontinuation trial designTheodore G Karrison
Lifetime Data Analysis|January 12, 2022
Nonparametric inference in the accelerated failure time model using restricted meansMihai C Giurcanu, Theodore G Karrison
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Testing the wrong hypothesis in phase II oncology trials: there is a better alternativeMark J Ratain, Theodore G Karrison
Journal of the National Cancer Institute|February 25, 2015
Building firm foundations for therapy developmentJames J Dignam, Theodore G Karrison
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2024
There Is More to Length of Survival Than Survival: Endpoints in Oncology TrialsWalter M Stadler, Theodore G Karrison
Controlled Clinical Trials|September 23, 2003
A group sequential, response-adaptive design for randomized clinical trialsTheodore G Karrison, Dezheng Huo, Rick Chappell
Blood Advances|June 21, 2022
D-dimer and risk for thrombosis in adults with newly diagnosed acute lymphoblastic leukemiaDaniela R Anderson, Wendy Stock, Theodore G Karrison, et al.
Journal of the National Cancer Institute|September 27, 2007
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancerTheodore G Karrison, Michael L Maitland, Walter M Stadler, et al.
Genetic Epidemiology|November 5, 2013
Quantitative allelic test--a fast test for very large association studiesSang Mee Lee, Theodore G Karrison, Nancy J Cox, et al.
The American Statistician|September 17, 2013
Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial DesignTheodore G Karrison, Mark J Ratain, Walter M Stadler, et al.
Pageof 7